Aptevo Therapeutics Inc. (APVO) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
2401 4TH AVE. SEATTLE, WA 98121 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 8,714 | 16,904 | 22,635 | 45,044 | 39,979 | 12,448 | |||
| Cash and cash equivalent | 8,714 | 16,904 | 22,635 | 45,044 | 39,979 | 12,448 | |||
| Restricted cash and investments | 1,259 | 2,555 | |||||||
| Receivables | 3,664 | 2,369 | 7,022 | ||||||
| Inventory, net of allowances, customer advances and progress billings | 6,139 | ||||||||
| Inventory | 6,139 | ||||||||
| Prepaid expense | 1,689 | 1,473 | 1,571 | 1,823 | 2,228 | 4,226 | |||
| Other current assets | 256 | 689 | 744 | 780 | 133 | 160 | |||
| Other undisclosed current assets | 2,500 | ||||||||
| Total current assets: | 10,659 | 19,066 | 27,450 | 52,570 | 47,264 | 29,995 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 4,389 | 4,881 | 5,303 | 1,584 | 2,722 | 3,747 | |||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | 543 | 895 | 1,462 | 2,379 | 2,815 | 3,946 | |||
| Intangible asset, including goodwill, after accumulated amortization | 4,420 | ||||||||
| Intangible asset, excluding goodwill, after accumulated amortization | 4,420 | ||||||||
| Restricted cash and investments | 7,498 | ||||||||
| Other noncurrent assets | 68 | 746 | 3,802 | ||||||
| Total noncurrent assets: | 4,932 | 5,776 | 6,765 | 4,031 | 6,283 | 23,413 | |||
| TOTAL ASSETS: | 15,591 | 24,842 | 34,215 | 56,601 | 53,547 | 53,408 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1,856 | 2,098 | 2,105 | 2,077 | 2,757 | 3,524 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 2,077 | 2,757 | 3,524 | ||
| Accounts payable | |||||||||
| Accrued liabilities | 1,856 | 2,098 | 2,105 | ||||||
| Debt | 2,000 | 11,667 | 5,000 | 19,863 | |||||
| Other liabilities | 1,298 | 1,142 | 1,102 | 2,086 | 1,199 | 1,083 | |||
| Other undisclosed current liabilities | 3,053 | 3,984 | 3,499 | 18,927 | 5,583 | 13,769 | |||
| Total current liabilities: | 6,207 | 7,224 | 8,706 | 34,757 | 14,539 | 38,239 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1,456 | 5,048 | 22,414 | 3,327 | |||||
| Long-term debt, excluding current maturities | 1,456 | 3,707 | 20,054 | ||||||
| Liabilities, other than long-term debt | 4,629 | 5,397 | 6,079 | ||||||
| Operating lease, liability | 4,629 | 5,397 | 6,079 | 1,341 | 2,360 | 3,327 | |||
| Other undisclosed noncurrent liabilities | 14,239 | (2,360) | |||||||
| Total noncurrent liabilities: | 4,629 | 5,397 | 7,535 | 20,628 | 22,414 | 3,327 | |||
| Total liabilities: | 10,836 | 12,621 | 16,241 | 55,385 | 36,953 | 41,566 | |||
| Equity | |||||||||
| Equity, attributable to parent | 4,755 | 12,221 | 17,974 | 1,216 | 16,594 | 11,842 | |||
| Common stock | 84 | 61 | 48 | 47 | 46 | 45 | |||
| Additional paid in capital | 252,248 | 235,607 | 223,962 | 215,232 | 202,154 | 179,653 | |||
| Accumulated deficit | (247,577) | (223,447) | (206,036) | (214,063) | (185,606) | (167,856) | |||
| Total equity: | 4,755 | 12,221 | 17,974 | 1,216 | 16,594 | 11,842 | |||
| TOTAL LIABILITIES AND EQUITY: | 15,591 | 24,842 | 34,215 | 56,601 | 53,547 | 53,408 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 12,500 | 12,292 | 4,309 | 32,424 | ||||
| Revenue from related parties | ✕ | ✕ | ✕ | 12,500 | ||||
| Cost of revenue (Cost of Product and Service Sold) | (19,927) | |||||||
| Gross profit: | 12,500 | 12,292 | 4,309 | 12,497 | ||||
| Operating expenses | (24,602) | (28,878) | (31,755) | (33,692) | (31,803) | (55,093) | ||
| Other undisclosed operating loss | (9,386) | |||||||
| Operating loss: | (24,602) | (28,878) | (28,641) | (21,400) | (27,494) | (42,596) | ||
| Nonoperating income (expense) | 472 | 10,228 | (1,527) | (8,008) | 14,338 | 2,148 | ||
| Investment income, nonoperating | 9,650 | 2,500 | 14,338 | 4,250 | ||||
| Other nonoperating income (expense) | 472 | 578 | (4,027) | (8,008) | (2,102) | |||
| Interest and debt expense | 37,182 | (2,105) | (2) | |||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (24,130) | (18,650) | 7,014 | (29,408) | (15,261) | (40,450) | ||
| Other undisclosed loss from continuing operations before income taxes | (15,662) | (4,248) | ||||||
| Income (loss) from continuing operations: | (24,130) | (18,650) | 7,014 | (29,408) | (30,923) | (44,698) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (28,457) | (17,750) | (40,448) | |
| Income from discontinued operations | 1,239 | 1,013 | 951 | 13,173 | 4,250 | |||
| Net income (loss) attributable to parent: | (24,130) | (17,411) | 8,027 | (28,457) | (17,750) | (40,448) | ||
| Preferred stock dividends and other adjustments | ||||||||
| Net income (loss) available to common stockholders, diluted: | (24,130) | (17,411) | 8,027 | (28,457) | (17,750) | (40,448) | ||
Comprehensive Income ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (24,130) | (17,411) | 8,027 | (28,457) | (17,750) | (40,448) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (24,130) | (17,411) | 8,027 | (28,457) | (17,750) | (40,448) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.